Utah is currently home to 1205 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334
Recruiting
This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 4041), Salt Lake City, Utah
Conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Salt Lake City, Utah
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: cGVHD
Register for Updates
Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05767385
Recruiting
Determine 1) the impact of abnormal fetal cerebrovascular physiology with neurodevelopmental delay (ND) outcomes and 2) how this relationship is modified by patient and environmental factors such as chronic congenital heart disease (CCHD) lesion, maternal-fetal environment, and social determinants of heath (SDOH) in a diverse population using a multicenter design. Pregnant women will be approached during one of their fetal cardiology clinic visits.
Gender:
FEMALE
Ages:
Between 0 years and 52 years
Trial Updated:
06/18/2025
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Congenital Heart Disease in Children, Hypoxia, Neurodevelopmental Disorders, Complex Congenital Heart Disease
Register for Updates
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NCT05591118
Recruiting
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Intermountain Health, Murray, Utah
Conditions: Pulmonary Embolism
Register for Updates
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245
Recruiting
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
06/18/2025
Locations: Cedar Clinical Research, Draper, Utah
Conditions: Autism Spectrum Disorder
Register for Updates
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Huntsman Cancer Hospital, Salt Lake City, Utah
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Register for Updates
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228
Recruiting
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/18/2025
Locations: Utah Cancer Specialists (site 203), Salt Lake City, Utah
Conditions: Mesothelioma, Ovarian Cancer, Adenoid Cystic Carcinoma, Cervical Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymic Carcinoma, Bladder Cancer, Pancreatic Cancer, Head and Neck Carcinoma, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Sarcoma, Esophageal Cancer, Uterine Cancer, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
Register for Updates
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
NCT02468024
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Intermountain Medical Center, Salt Lake City, Utah
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637
Recruiting
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Utah Cancer Specialists, Bountiful, Utah
Conditions: Breast Cancer
Register for Updates
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
NCT06746402
Recruiting
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/17/2025
Locations: ICON Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Volunteers
Register for Updates
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489
Recruiting
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/17/2025
Locations: Andes Clinical Research, Orem, Utah
Conditions: Major Depressive Disorder
Register for Updates